Steinert Disease
7
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
43%
3 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (7)
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Global Study of Del-desiran for the Treatment of DM1
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
The Spanish National Registry for Myotonic Dystrophy Type 1
Myotonic Dystrophy Family Registry
Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy